Meta-analysis of association between rs1447295 polymorphism and prostate cancer susceptibility

Juan Zhou; Yang Yu; Anyou Zhu; Fengchao Wang; Fengchao Wang; Shuxia Kang; Yunfeng Pei; Chunping Cao; Chen Ding; Duping Wang; Guoping Niu; Guoping Niu

doi:10.18632/oncotarget.17627

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Meta-analysis of association between rs1447295 polymorphism and prostate cancer susceptibility

Juan Zhou _, Yang Yu, Anyou Zhu, Fengchao Wang, Fengchao Wang, Shuxia Kang, Yunfeng Pei, Chunping Cao, Chen Ding, Duping Wang, Guoping Niu and Guoping Niu

PDF | HTML | How to cite

Oncotarget. 2017; 8:67029-67042. https://doi.org/10.18632/oncotarget.17627

Metrics: PDF 1290 views | HTML 2069 views | ?

Abstract

Juan Zhou1,*, Yang Yu2,*, Anyou Zhu3,*, Fengchao Wang3, Shuxia Kang3, Yunfeng Pei1, Chunping Cao1, Chen Ding1, Duping Wang1, Li Sun1 and Guoping Niu1

1Department of Clinical Laboratory, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People’s Republic of China

2Department of Medical Oncology, Affiliated to Medical College of Southeast University and Xuzhou Central Hospital, Xuzhou, People’s Republic of China

3Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Anhui, People’s Republic of China

*These authors have contributed equally to this work

Correspondence to:

Anyou Zhu, email: [email protected]

Keywords: meta-analysis, rs1447295, prostate cancer, susceptibility

Received: June 30, 2016 Accepted: March 04, 2017 Published: May 05, 2017

ABSTRACT

Aims: A number of studies have found that the single nucleotide polymorphisms (SNPs) within the 8q24 region of genome were associated with the susceptibility of prostate cancer. Association between 8q24 SNP variant rs1447295 and higher risk of prostate cancer had been investigated, but those studies were incomplete and the conclusions were obscure.

Methods: To better elucidate the relationship between rs1447295 polymorphism and the susceptibility of prostate cancer, we performed a more comprehensive meta-analysis about the association between rs1447295 polymorphism and prostate cancer susceptibility by collecting relevant articles published up to November, 2016 and excluding many replicated cohort data existing in previous reports, which made the conclusion more reliant and objective.

Results: The results showed that there was a significant prostate cancer risk associated with rs1447295 polymorphism not only in the total groups, but also in American, European and Asian descent subgroups. Meanwhile, a comprehensive analysis about the association between rs1447295 polymorphism and prostate cancer risk were conducted by using different clinical characteristic stratifications including Gleason score, tumor stage and PSA level. The result showed that rs1447295 polymorphism was correlated with different stages of prostate cancer

Conclusions: There are strong association between rs1447295 polymorphism and prostate cancer susceptibility in different ethnic groups and different prostate cancer stage, suggesting that rs1447295 might serve as a reliable biomarker for prostate cancer diagnosis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 17627

Publication Alerts

Research Papers:

Meta-analysis of association between rs1447295 polymorphism and prostate cancer susceptibility

Abstract